News
Access Vascular Supports Updated Standards of Care Emphasizing New Materials to Reduce Catheter Complications
Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.
Access Vascular Appoints MedTech Veteran to Head MIMIX™ Commercialization
Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced the appointment of Dennis Byrne to the newly created role of Vice President of Sales and Marketing.
Access Vascular to Ramp Production With $22 Million Series C Financing
“AVI is poised to have a substantial impact on vascular access complications and their associated costs,” said James Biggin, founder and CEO of Access Vascular. “This funding, coupled with increasing demand for our ground-breaking catheters, and new data showing reduced bacterial adhesion, is yet another milestone on our path to transforming the standard of care for vascular access.”
Access Vascular Highlights New Bacterial Adhesion Data at AVA 2023
The study, results of which were shared Oct. 14 at the annual scientific meeting of the Association for Vascular Access, compared bacterial adhesion on two polyurethane-based catheters and the HBM using in vitro blood flow and static models. The HBM demonstrated a 99.998 percent reduction in bacterial adhesion compared with the standard polyurethane catheter, and a 99.989 percent reduction compared with an augmented polyurethane material.
Access Vascular Inc. Announces Publication of Study Showing Significantly Reduced Failure Rates with its HydroPICC® Catheter
Access Vascular, Inc. (AVI), a medical device company addressing the most common and costly complications of intravenous therapy, today announced the publication of a peer-reviewed study of its HydroPICC® peripherally inserted central catheter (PICC) in the Journal of Materials Science: Materials in Medicine.
Riverside Medical Center Performs First In-Patient Use of Biomaterial-Based HydroPICC® Dual Lumen Catheter
Access Vascular, Inc. (AVI) today announced that Riverside Medical Center, located just outside the Chicago area, was the first in the nation to use its HydroPICC® Dual-Lumen catheter in a patient. Made from a proprietary hydrophilic biomaterial featuring MIMIX™ technology…
Access Vascular Integrative Review Published in International Journal of Nursing and Healthcare Research Establishes Economic Impact of Biomaterial Catheters
Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared key findings from an economic analysis published in the International Journal of Nursing and Research regarding AVI’s consistently hydrophilic PICC and midline catheters. The analysis documents millions of dollars in available cost-savings for hospitals using biomaterial-based catheters to reduce vascular access complications.
Journal of Infusion Nursing Publishes Access Vascular Data Showing Significantly Reduced Complication Rates for HydroMID
Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today announced the outcome of a peer-reviewed study published in the Journal of Infusion Nursing that demonstrated a significant reduction in complications when using AVI’s consistently hydrophilic midline catheters.
New Access Vascular Retrospective Data Review Demonstrates Midline Catheters Composed of Advanced Biomaterials May Improve Dwell Times
Access Vascular, Inc. (AVI) today shared initial findings from a retrospective review of patient records that demonstrates an increase in dwell times compared to other commercially-available devices and no complications when using AVI’s consistently hydrophilic materials for midline catheters.
Access Vascular Inc. Named 2022 MedTech Breakthrough Award Winner
Access Vascular, Inc. (AVI) today announced it has been named “Best New Technology Solution – Drug Delivery” in the 2022 MedTech Breakthrough Awards. AVI’s patented, groundbreaking new biomaterial-based catheters were recognized for their potential to reshape the field of vascular access and value based care at large.
Access Vascular Receives FDA Clearance for HydroPICC® Biomaterial-Based Dual-Lumen Catheter
Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC® Dual-Lumen catheter. Designed and constructed using the same proprietary hydrophilic biomaterial as AVI’s single-lumen HydroPICC® and HydroMID® catheters, these devices showed significant reduction in complications such as occlusions, replacements, Deep Vein Thrombosis and phlebitis in recent studies.
Access Vascular Inc. Wins 2022 Edison Award for Innovation
Access Vascular, Inc. (AVI) today announced its biomaterial-based hydrophilic catheters received a Gold Award as the 2022 Edison Best New Product in science and medical at the 2022 Edison Awards™.
Access Vascular, Inc. Opens New Facility Outside Boston With Expanded Production Capacity to Meet Growing Demand for Its Biomaterial Devices
New 40,000 sqft facility offers additional advanced manufacturing capabilities as providers seek to improve medical outcomes using Access Vascular’s catheters.
Access Vascular Inc. Partners with Healthcare Insights to Develop New MedTech Value-Based Care Program
Access Vascular, Inc. (AVI), today announced its partnership with Healthcare Insights (HCIS) to build a value-based care program that can more broadly support hospital customers as they deploy the company’s groundbreaking biomaterial-based catheters to improve vascular access medical and economic outcomes.
Access Vascular Inc. Named 2022 BIG Innovation Award Winner
AVI’s groundbreaking new biomaterial-based cathethers were recognized for their ability to nearly eliminate the common and expensive complications that affect approximately 30% of all hospital patients with traditional polyurethane catheters inserted. This transformational technology has the potential to reshape the field of vascular access and value based care at large.
Access Vascular Inc. and Eloquest Healthcare Partner to Improve Vascular Access Outcomes
“Eloquest Healthcare is known for delivering innovative solutions that improve the standard of care with an emphasis on infection prevention and enhanced patient satisfaction, making them a perfect partner for Access Vascular,” said James Biggins, CEO at Access Vascular Inc. “Our mission is to eliminate complications like catheter thrombosis, phlebitis and resulting infections, thereby improving the efficacy of vascular access procedures. This partnership will help us carry that mission further and faster.”
New Access Vascular Clinical Studies Find Catheters Composed of Advanced Biomaterials Significantly Reduce Complication Rates
Data presented at the AVA Annual Scientific Meeting shows impactful reductions in occlusions, DVT, and phlebitis using materials that mimic the body’s chemistry
Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared initial findings from two new clinical studies that demonstrate a significant reduction in complications when using AVI’s consistently hydrophilic materials for peripherally inserted central catheters (PICC) and midline catheters.
Access Vascular Inc. and Association for Vascular Access partner to champion clinicians leading care transformation at their institutions
Despite incremental changes to catheter design and placement techniques, catheter related complication rates remain unacceptably high and range between 30% and 34%1,2. Complications such as catheter related thrombosis, phlebitis and infections impact patient safety, increase total medical costs, and create frustration for clinicians.
Access Vascular, Inc. Secures $20 Million in Series B Financing
Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. TVM Capital Life Science led the round with a $15 million commitment, with existing investors also participating.
HydroMID Midline Catheter from Access Vascular Receives FDA Clearance
Access Vascular, Inc. today announced FDA clearance of its HydroMID™ midline catheter. HydroMID, which is made of Access Vascular’s proprietary biomaterial that has been shown to reduce thrombus accumulation by up to 97 percent when compared to standard polyurethane catheters,1 is the second device in its planned portfolio to obtain clearance.